灵康药业：关于变更回购股份用途并注销暨减少注册资本的公告

Core Viewpoint - Lingkang Pharmaceutical announced a change in the purpose of its repurchased shares, shifting from an employee stock ownership plan and equity incentive to cancellation and reduction of registered capital [1] Summary by Relevant Sections - Company Announcement - On January 30, 2026, Lingkang Pharmaceutical will hold its sixth meeting of the fifth board of directors to review the proposal regarding the change in the purpose of repurchased shares and the cancellation of shares [1] - Share Repurchase Details - The company has 8,915,893 shares in its repurchase account that are currently unused [1] - Change in Usage of Shares - The intended use of the repurchased shares has been altered from "50% for employee stock ownership plan and 50% for equity incentives" to "for cancellation and reduction of registered capital" [1]